Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.0K
2.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The metabolic plasticity of cancer stem cells: bidirectional crosstalk with organ-resident cells.

Experimental & molecular medicine·2026
Same author

α-Viniferin Induces Intrinsic Apoptosis in Triple-Negative Breast Cancer Cells and Synergizes With SB203580 Independently of p38 Mitogen-Activated Protein Kinase.

Journal of breast cancer·2026
Same author

Loss of ABCA3 disrupts lipid balance and leads to AMPK-dependent suppression of SREBP1 in glioblastoma stem cells.

Oncogene·2026
Same author

Retinoic acid signaling regulates astrocyte reactivity by modulating MAPK/NF-κB pathways and mitochondrial integrity.

Neurochemistry international·2026
Same author

Cytoplasmic LIM domain only 2 enhances tumor endothelial cell migration through integrin β1-mediated focal adhesion signaling.

Acta neuropathologica communications·2026
Same author

DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species.

Nature communications·2025

Related Experiment Video

Updated: Apr 28, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

16.5K

Molecular culprits generating brain tumor stem cells.

Se-Yeong Oh1, Hyunggee Kim1

  • 1School of Life Science and Biotechnology, Korea University, Seoul, Korea.

Brain Tumor Research and Treatment
|June 7, 2014
PubMed
Summary
This summary is machine-generated.

High-grade glioma remains fatal despite treatments. Brain tumor stem cells (BTSCs) resist therapy, driving recurrence, and represent a key target for new treatments.

Keywords:
Brain tumor stem cellBrain tumor stem cell reprogrammingCancer stem cell nicheHigh-grade gliomaReprogramming factors

More Related Videos

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

17.8K
Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
09:36

Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion

Published on: August 29, 2018

10.7K

Related Experiment Videos

Last Updated: Apr 28, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

16.5K
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

17.8K
Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
09:36

Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion

Published on: August 29, 2018

10.7K

Area of Science:

  • Neuro-oncology
  • Cancer Stem Cell Biology

Background:

  • High-grade glioma (HGG) has a poor prognosis despite multimodal therapies.
  • Brain tumor stem cells (BTSCs) are implicated in therapeutic resistance and tumor recurrence in HGG.

Purpose of the Study:

  • To highlight the critical role of BTSCs in HGG treatment failure.
  • To propose BTSCs as a primary therapeutic target for improved HGG outcomes.

Main Methods:

  • Review of current literature on HGG therapy and BTSC characteristics.
  • Analysis of BTSC properties, including self-renewal and differentiation.
  • Evaluation of BTSC resistance mechanisms to standard treatments.

Main Results:

  • BTSCs exhibit stem cell-like properties, contributing to treatment resistance.
  • The infiltrative nature and therapy resistance of BTSCs are primary drivers of HGG recurrence.
  • BTSCs possess unique characteristics that differentiate them from bulk tumor cells.

Conclusions:

  • Targeting BTSCs is crucial for overcoming therapeutic resistance in high-grade glioma.
  • Elimination of BTSCs offers a promising strategy for achieving successful HGG treatment outcomes.
  • Further research into BTSC-specific therapies is warranted to improve patient survival rates.